Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 TMP induction therapy in transplant-ineligible newly diagnosed multiple myeloma
jRCT2080222743Phase 2
- Sponsor
- Fujimoto Pharmaceutical
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple myeloma (MM) comparing Thalidomide + melphalan + prednisolone with Placebo + melphalan + prednisolone (2 arms).
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080222743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222743.